When LAMP-2 decline was used to identify biochemical response at 3 months of UDCA therapy among the 102 patients with PBC, the area under the ROC (Receiver Operating Characteristic) curve for LAMP-2 decline was 0.741 (95%CI: 0.641-0.840; Fig. 5a) by Paris criteria, or 0.717 (95%CI: 0.614-0.820; Fig. 5b) by Barcelona criteria. Here, LAMP2 is linked to primary biliary cholangitis.